Earnings summaries and quarterly performance for Catheter Precision.
Executive leadership at Catheter Precision.
Board of directors at Catheter Precision.
Research analysts covering Catheter Precision.
Recent press releases and 8-K filings for VTAK.
Catheter Precision, Inc. Enters Securities Purchase Agreement for Convertible Preferred Stock and Common Stock
VTAK
Convertible Preferred Issuance
New Projects/Investments
- Catheter Precision, Inc. (VTAK) entered into a Securities Purchase Agreement on February 6, 2026, to sell newly authorized Series C Convertible Preferred Stock (stated value $1,000 per share) and Common Stock to various investors.
- The proceeds from the sale will be used for general corporate and working capital purposes, to restructure the Company's legacy catheter business, satisfy legacy liabilities, simplify the capital structure, and reduce operating expenses and cash burn. Proceeds from Tranche 1 will specifically repay the Bridge Note.
- The Series C Preferred Stock is convertible into Common Stock and has a liquidation preference over Junior Securities, entitling holders to the stated value plus accrued unpaid dividends upon liquidation.
- The Company is required to reserve 100% of the maximum Common Stock shares for conversion of outstanding Preferred Shares and is prohibited from engaging in Variable Rate Transactions. Additionally, the Common Stock must maintain its listing on the Principal Market, and its closing price must be at least $0.35 prior to each closing.
8 hours ago
Catheter Precision Reports Strong Q3 2025 Revenue Growth and Reduced Net Loss
VTAK
Earnings
Revenue Acceleration/Inflection
Guidance Update
- Catheter Precision, Inc. (VTAK) reported total revenue of $226,000 for Q3 2025, representing a 135% increase compared to Q3 2024.
- For the nine months ended September 30, 2025, total revenue was $581,000, an increase of 114% over the same period in 2024.
- The company's GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to the $4,120,000 loss in Q3 2024.
- Sales activities for both LockeT and VIVO products are increasing outside the United States, with LockeT receiving CE Mark approval and VIVO gaining traction, including a first purchase order from France.
- CEO David Jenkins projects a pivotal period of growth over the coming year, anticipating a major expansion of approved product lines across US and international markets, supported by completed VIVO clinical studies in 2025.
Nov 14, 2025, 10:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more